An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice Violations
Crossref DOI link: https://doi.org/10.1007/s43441-021-00267-y
Published Online: 2021-06-08
Published Print: 2021-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jung, Miah
Swann, Rachelle M.
Anantha, Michelle S.
Jamali, Faranak
Text and Data Mining valid from 2021-06-08
Version of Record valid from 2021-06-08
Article History
Received: 22 September 2020
Accepted: 25 February 2021
First Online: 8 June 2021
Declarations
:
: No potential conflicts were declared.